Nightingale Health, the Finnish innovator of an award-winning blood testing technology, today announced that it has earned certification (SFS-EN ISO/IEC 17025:2005) for its laboratory from the Finnish Accreditation Service FINAS.

The ISO 17025:2005 standard specifies the quality management and technical requirements that laboratories must meet in order to demonstrate technical competency and adherence to strict quality measures for testing, data reporting and process control in the laboratory. The scope of Nightingale’s accreditation covers the company’s clinical service methods.

The ISO 17025:2005 accreditation follows Nightingale’s successful CE Marking of its technology in 2017, enabling clinical use of its technology in Europe, with the company’s Quality Management System certified to EN ISO 13485:2016. “Nightingale is committed to continuous improvement and nowhere is this more important than in delivering our clinical service to the highest standard,” said Marjut Vähäheikkilä, Head of Health, Safety, Environment and Quality. “The ISO 17025 certification demonstrates our technical competency to provide accurate and precise results to our customers that can be compared with other clinical labs.”

FINAS accreditation is a vital next step in Nightingale’s mission to accelerate breakthroughs in chronic disease prevention. The company is investing and working towards integrating its technology into clinical practice to bring about precision medicine – tailoring health assessment and treatments to the individual and empowering patients to take proactive steps to stay healthy. “From the beginning we’ve put quality and the needs of regulatory requirements at the centre of our strategy,” said Teemu Suna, Nightingale’s CEO and Founder. “This accreditation demonstrates our ability to maintain our commitment to quality, whilst also effectively scaling up our operations and services to meet market demand.”

Teemu Suna
Founder, CEO
Nightingale Health
p. +358 40 196 1669
press@nightingalehealth.com

Nightingale Health is a biotech company aiming to solve the global burden of chronic disease. We believe that rather than solely focusing on treatments, health should be about keeping people healthy. We develop pioneering solutions that facilitate active prevention of chronic diseases, such as cardiovascular diseases and diabetes. With our proprietary blood testing technology, we reveal unique molecular insights that are invisible using standard technologies. This broader visibility allows us to predict the future risk of a person developing a disease, empowering people to make a positive impact on their health.